Fundraising Fox
PrognomIQ
San Mateo, US · Founded 2020 · Delaware corporation · 40 employees on LinkedIn · 4 known investors
Find your way into PrognomIQ
Sign up to see every warm intro you have to PrognomIQ
- Paths you didn't know you had: your email and LinkedIn already hold routes to the PrognomIQ team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
PrognomiQ is a clinical-stage company developing blood-based tests for early detection and treatment of cancer and other complex diseases using multi-omics data. It combines proprietary large-scale proteomic data with genomic, metabolomic, and other health data on its own platform to build diagnostic test products.
Founders & leadership
PrognomIQ was founded in 2020 by Philip Ma, Ph.D., Philip Ma, and Omid Farokhzad.
PM
Philip Ma, Ph.D.Co-founder
PM
Philip MaChief Executive Officer & FounderPreviously, he served as Chief Business Officer and Executive Vice President at Seer, held leadership roles in digital health and data sciences at Biogen, and was a senior partner at McKinsey focused on R&D and corporate development strategy.
BW
Bruce WilcoxChief Technology OfficerHe has over 20 years of experience in analytical measurement across diverse applications and has led the development of blood-based diagnostic tests, including the SimpliPro Colon CRC test, bringing proteomics approaches toward clinical application.
OF
Omid Farokhzad, M.D.Named on SEC filing
Board
TB
Tomer Berkovitz, Ph.D.Board director
RG
Rajesh GargBoard director
MM
Mark McClellan, M.D., Ph.D.Board director
IR
Investors · 4
aMoonlisted by aMoonRa'anana
How we know: aMoon's portfolio page · a partner's Signal profile · Not right? Tell us
Catalio Capital Management, LPlisted by Catalio Capital Management, LPNew York
How we know: Catalio Capital Management, LP's portfolio page · Not right? Tell us
Maverick VenturesreportedSan Francisco · $3M – $10M
How we know: the VCSheet dataset · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$56.2M disclosed across 3 rounds · 2024–2026
▶$11.9MraisedJan 2026 · 6 investors · Other Health CareRule 506(b)
▶$11.9MraisedJan 2026 · 6 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Rajesh Garg, M.D.Director
- Brian Koh, M.D.Executive Officer
- Omid C. Farokhzad, M.D.Director
- Bruce Wilcox, Ph.D.Executive Officer
- Isaac Ro, Ph.D.Director
- David L. SiewersExecutive Officer
- Mark B. McClellan, M.D., Ph.D.Director
- Philip Ma, Ph.D.Executive Officer, Director
- Tomer Berkovitz, Ph.D.Director
- Offering amount
- $11.9M
- Amount sold
- $11.9M
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MraisedAug 2025 · 9 investors · Other Health CareRule 506(b)
▶$10MraisedAug 2025 · 9 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Rajesh Garg, M.D.Director
- Mark B. McClellan, M.D., Ph.D.Director
- Philip Ma, Ph.D.Executive Officer, Director
- Bruce Wilcox, Ph.D.Executive Officer
- Joel KaufmanExecutive Officer
- Omid C. Farokhzad, M.D.Director
- Isaac Ro, Ph.D.Director
- Tomer Berkovitz, Ph.D.Director
- Brian Koh, M.D.Executive Officer
- Offering amount
- $10M
- Amount sold
- $10M
- First sale
- Aug 2025
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$34.3MraisedAug 2024 · 10 investors · Other Health CareRule 506(b)
▶$34.3MraisedAug 2024 · 10 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Rajesh GargDirector
- Philip Ma, Ph.D.Executive Officer, Director
- Omid Farokhzad, M.D.Director
- Tomer Berkovitz, Ph.D.Director
- Mark McClellan, M.D., Ph.D.Director
- Brian Koh, M.D.Executive Officer
- David SiewersExecutive Officer
- Isaac RoDirector
- Offering amount
- $34.3M
- Amount sold
- $34.3M
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through PrognomIQ went on to found or lead other companies.
Related companies · 6
Nomic BioNomic offers an end-to-end protein profiling service built on its nELISA technology, quantifying up to 1000 informative proteins with absolute quantification for research studies. It targets researchers doing proteomics work, aiming for high-throughput, low-cost profiling in the biotech and life sciences market.
Phenomic AIPhenomic AI is a biotech company developing therapies for solid tumors using a machine-learning-powered transcriptomics platform that analyzes single-cell RNA data to identify drug targets and understand tumor biology. The company develops antibody-based therapies informed by its analysis of cell-cell interactions in tumor microenvironments, with current programs targeting stromal and immune components of difficult-to-treat cancers.
Predictive OncologyPredictive Oncology develops drug discovery solutions for biopharma companies that combine artificial intelligence with a proprietary biobank of over 150,000 tumor samples to accelerate oncology drug development and improve therapeutic outcomes for cancer patients.
IDbyDNAScalable, high throughput DNA sequencing platforms.
Nautilus BiotechnologyNautilus develops proteomics technology to unlock the complexity of the human proteome for biomedical research and diagnostics. The company targets pharmaceutical, biotechnology, academic, clinical, and government sectors with advanced protein quantification and analysis platforms.
Macrogenics IncMacroGenics is a clinical-stage biopharmaceutical company developing antibody-based therapies for cancer patients. It advances a pipeline of product candidates using proprietary platforms for antibody-drug conjugates, bispecific checkpoint antibodies, and T-cell engagers.
Companies working in the same space as PrognomIQ.
Frequently asked questions
- What does PrognomIQ do?
- PrognomiQ is a clinical-stage company developing blood-based tests for early detection and treatment of cancer and other complex diseases using multi-omics data. It combines proprietary large-scale proteomic data with genomic, metabolomic, and other health data on its own platform to build diagnostic test products.
- Who founded PrognomIQ?
- PrognomIQ was founded by Philip Ma, Ph.D., Philip Ma, Omid Farokhzad in 2020.
- Who are PrognomIQ's investors?
- PrognomIQ's investors include aMoon, Catalio Capital Management, LP, Wing, Maverick Ventures.
- How much funding has PrognomIQ raised?
- PrognomIQ has disclosed $56.2M raised across 3 rounds.
- Where is PrognomIQ headquartered?
- PrognomIQ is headquartered in San Mateo, US.